FDA Delays Approval Of AstraZeneca Unit's Potassium Drug
The U.S. Food and Drug Administration has initially rejected a drug to treat high potassium levels made by a newly acquired AstraZeneca unit, citing manufacturing issues, the London-based drugmaker said Friday....To view the full article, register now.
Already a subscriber? Click here to view full article